Back to Search Start Over

The impact of antibiotic use in gastrointestinal tumors treated with immune checkpoint inhibitors: systematic review and meta-analysis.

Authors :
Alotaibi FM
Albalawi IAS
Anis AM
Alotaibi H
Khashwayn S
Alshammari K
Al-Tawfiq JA
Source :
Frontiers in medicine [Front Med (Lausanne)] 2024 Jun 03; Vol. 11, pp. 1415093. Date of Electronic Publication: 2024 Jun 03 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Immune checkpoint inhibitors (ICI) have improved overall survival in patients with different cancer types. However, treatment efficacy varies between patients depending on several factors. Recent research suggested that antibiotic-induced dysbiosis can impair ICI efficacy. Here we review the impact of antibiotic use in clinical outcome of patients with gastrointestinal cancer treated with ICI.<br />Methods: This is a systematic review and utilized a thorough search of MEDLINE, Cochrane, Scopus, EB-SCO, Web of Science of studies published till September 2023. The aim of the study is to determine the association between antibiotic use and ICI treatment efficacy in patients with gastrointestinal cancers (GI). We utilized a meta-analysis of the association between the use of antibiotics and overall survival and progression-free survival.<br />Results: Nine studies met the inclusion criteria with a total of 2,214 patients. The most common type of cancers was hepatocellular carcinoma (HCC). The majority of the studies were retrospective, and one was collective of clinical trials. The use of antibiotics was associated with decreased both overall survival [haz-ard ratio (HR) 1.92, 95% confidence interval (CI) 1.41, 2.63] and progression-free survival [HR 1.81, 95% CI 1.29, 2.54].<br />Conclusion: The use of antibiotics may affect clinical outcomes in patients with GI cancers treated with ICI. Further prospective studies are needed to improve the understanding of this phenomenon.<br />Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023462172.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Alotaibi, Albalawi, Anis, Alotaibi, Khashwayn, Alshammari and Al-Tawfiq.)

Details

Language :
English
ISSN :
2296-858X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in medicine
Publication Type :
Academic Journal
Accession number :
38887674
Full Text :
https://doi.org/10.3389/fmed.2024.1415093